Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With BAT1308 in Patients With Advanced Solid Tumors

This first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of BAT6021 alone or in combination with BAT1308 (an anti-PD-1 antibody) in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

Study Overview

• Status: Terminated
• Conditions: Advanced Solid Tumor
• Intervention / Treatment: Drug: BAT1308; Drug: BAT6021

Detailed Description

Anti-PD-1 and anti-PD-L1 antibodies targeting the immuno-inhibitory PD-1 pathway (thus activating T cells) have achieved clinical success in many types of cancers. However, studies have shown that anti-TIGIT antibodies not only trigger T cells and Natural Killer(NK) cells, but they can also activate T cells to a greater extent than anti-PD-1 antibodies. Therefore, further clinical investigation of anti-TIGIT antibodies such as BAT6021 is warranted.

PD-1 and TIGIT are commonly co-expressed in T cells of the same tumor; thus, combining anti-TIGIT antibodies with PD-1/PD-L1 inhibitors may be a more effective cancer treatment. Indeed, anti-TIGIT antibodies have demonstrated synergy with anti-PD-1/PD-L1 antibodies in preclinical models. In addition, sponsor have shown that single administration of BAT1308 or BAT6021 could not effectively inhibit CT26 tumor growth in PD-1/TIGIT- humanized syngeneic mice; however, the combination treatment resulted in potent anti-tumor activity. Therefore, combined treatment with BAT6021 and an anti-PD-1/PD-L1 antibody like BAT1308 could improve therapeutic outcomes.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Liverpool, New South Wales, Australia
      • Liverpool Hospital
    • Sydney, New South Wales, Australia
      • Macquarie University Hospital
  • Victoria
    • Melbourne, Victoria, Australia
      • Cabrini Hospital Malvern

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures.
2. Aged ≥ 18 years.
3. Life expectancy ≥ 3 months.
4. ECOG performance status ≤ 1.
5. Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors that are refractory to standard therapy, or for whom no standard therapy exists.
6. Has measurable disease per RECIST v1.1. that was not in a prior radiation or other locally treated area, unless imaging-based progression has been clearly documented following radiation or other local therapy.

Exclusion Criteria:

1. Females who are pregnant or nursing.
2. Receiving concurrent anticancer therapy or investigational therapy (including chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy).
3. Has remaining AEs > Grade 1 from prior antitumor treatment as per CTCAE v5.0, with the exception of alopecia.
4. Participants with primacy central nervous system (CNS) malignancy, symptomatic CNS metastases, meningeal metastases or leptomeningeal disease are not allowed. Note: Participants with asymptomatic CNS metastases are eligible if clinically controlled, which is defined as 1) ≥ 4 weeks of stable neurologic function following CNS-directed therapy prior to Screening, 2) no evidence of CNS disease progression as determined by radiographic imaging ≥ 4 weeks prior to Screening, 3) ≥ 2 weeks from discontinuation of anti-seizure and steroid therapies (receiving prednisone ≤ 10mg or equivalent steroid therapies is allowed) prior to Screening.
5. Had major surgery within 28-days of the Screening Visit. Note: Participants who have undergone a non-major surgical procedure ≥ 28 days prior to Screening must have recovered adequately from the toxicity and/or complications from the intervention before administration of the first dose of study drugs.
6. History of tissue or organ transplantation.
7. History of severe infection deemed clinically significant by the PI or designee within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose of study drugs.
8. History of human immunodeficiency virus (HIV) infection or history of autoimmune diseases.
9. Active hepatitis B or C. Note: Hepatitis B virus (HBV) carriers without active disease (HBV DNA titer < 1000 copies/mL or 200 IU/mL) or cured Hepatitis C (negative HCV RNA test) may be enrolled.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

9

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 10 mg of BAT6021; BAT6021 100mg/vial，10mg Ⅳ infusions	Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 30 mg of BAT6021; BAT6021 100mg/vial，30mg Ⅳ infusions	Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 100 mg of BAT6021; BAT6021 100mg/vial，100mg Ⅳ infusions	Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 300 mg of BAT6021; BAT6021 100mg/vial，300mg Ⅳ infusions	Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 600 mg of BAT6021; BAT6021 100mg/vial，600mg Ⅳ infusions	Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 900 mg of BAT6021; BAT6021 100mg/vial，900mg Ⅳ infusions	Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 100mg BAT6021+300mg BAT1308; BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions	Drug: BAT1308; Ⅳ infusions; Other Names: Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection; Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 300mg BAT6021+300mg BAT1308; BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions	Drug: BAT1308; Ⅳ infusions; Other Names: Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection; Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection
Experimental: 600mg BAT6021+300mg BAT1308; BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions	Drug: BAT1308; Ⅳ infusions; Other Names: Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection; Drug: BAT6021; Ⅳ infusions; Other Names: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose-limiting toxicity(DLT)	DLT is defined as one of the following as investigator related to study drug: Grade 5 toxicity; Hematologic Toxicity ; ≥ Grade 4 anemia; Grade 4 thrombocytopenia that lasts for ≥ 7 days or Grade 3 thrombocytopenia, if associated with clinically significant bleeding (≥ Grade 2 hemorrhage) or requires transfusion of platelets; Grade 4 neutropenia that lasts for ≥ 7 days, or Grade 3 neutropenia that lasts for ≥ 7 days or with documented infection; Grade 3 or Grade 4 febrile neutropenia of any duration.	A minimum of 21 days after first dose of BAT6021
Serious adverse event（SAE）	Any SAE that is judged by the PI or designee to be related to the study medication must be reported regardless of the amount of time since the last dose received. Follow-up information collected for any initial report of an SAE must also be reported to the Sponsor (or its designee) within 24 hours of receipt by the PI or designee.	From the time of informed consent to 90 days after the last dose or until the initiation of a new cancer treatment.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK)	Cmax	every cycle until cycle 6 (one cycle equals 3 weeks)
Immunogenicity	Presence of ADAs / neutralizing antibodies (NAbs).	every cycle until cycle 6 (one cycle equals 3 weeks)

Collaborators and Investigators

• Sponsor: Bio-Thera Solutions
• Investigators: Principal Investigator: Abhijit Pal, M.D, Ph.D, Medical Oncologist at cancer Therapy, Liverpool Hospital

Study record dates

Study Major Dates

• Study Start (Actual): October 29, 2021
• Primary Completion (Actual): March 30, 2023
• Study Completion (Actual): March 30, 2023

Study Registration Dates

• First Submitted: September 9, 2021
• First Submitted That Met QC Criteria: September 28, 2021
• First Posted (Actual): October 11, 2021

Study Record Updates

• Last Update Posted (Actual): October 11, 2023
• Last Update Submitted That Met QC Criteria: October 9, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Immunoglobulins
• Other Study ID Numbers: BAT-6021-002-CR

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: no plan to share IPD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No